@article{article, title = {{Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial}}, publisher = {{Elsevier BV}}, url = {{http://dx.doi.org/10.1016/s2352-3026(24)00249-7 }}, year = {{2024}}, month = {{9}}, author = {{Cook G and Ashcroft AJ and Senior E and Olivier C and Hockaday A and Richards J and Cavenagh JD and Snowden JA and Drayson MT and de Tute R and Roberts L et al}}, doi = {{10.1016/s2352-3026(24)00249-7}}, journal = {{The Lancet Haematology}}, pages = {{S2352-3026(24)00249}}, note = {{Accessed on 2025/07/04}}}